Cargando…

Long-term efficacy of immune checkpoint inhibitors in advanced NSCLC: challenges and opportunities—a commentary of the 3-year follow-up of the KEYNOTE-001 trial

Detalles Bibliográficos
Autores principales:	Russo, Alessandro, Scilla, Katherine A., Rolfo, Christian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2019
Materias:	Editorial Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8797642/ https://www.ncbi.nlm.nih.gov/pubmed/35117140 http://dx.doi.org/10.21037/tcr.2019.06.24

Ejemplares similares

Long-term efficacy of immune checkpoint inhibitors with or without chemotherapy in recurrent or metastatic squamous cell carcinoma of the head and neck: a commentary on the 4-year follow-up of the KEYNOTE-048 trial
por: Sano, Daisuke, et al.
Publicado: (2023)

Commentary: Teleophthalmology: Opportunities and challenges
por: Vazirani, Jayesh
Publicado: (2020)

Long-term outcomes in patients with advanced melanoma who had initial stable disease with pembrolizumab in KEYNOTE-001 and KEYNOTE-006
por: Hamid, Omid, et al.
Publicado: (2021)

Immune Checkpoint Inhibitors and Radiotherapy in NSCLC Patients: Not Just a Fluke
por: Belluomini, Lorenzo, et al.
Publicado: (2019)

Combining STAT3-Targeting Agents with Immune Checkpoint Inhibitors in NSCLC
por: Papavassiliou, Kostas A., et al.
Publicado: (2023)

Gene expression profiles (GEPs) of immuno-oncologic pathways as predictors of response to checkpoint inhibitors in advanced NSCLC
por: De Marchi, Pedro, et al.
Publicado: (2023)

Commentary: PROTACs make undruggable targets druggable: Challenge and opportunity
por: Lu, Bin, et al.
Publicado: (2021)

Breakthrough 5-year survival with pembrolizumab in Keynote-001 study: horizon shifting in advanced non-small cell lung cancer with immune check point inhibition
por: de Silva, Madhawa, et al.
Publicado: (2020)

Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001
por: Hamid, O, et al.
Publicado: (2019)

Outcomes With Pembrolizumab Monotherapy in Patients With Programmed Death-Ligand 1–Positive NSCLC With Brain Metastases: Pooled Analysis of KEYNOTE-001, 010, 024, and 042
por: Mansfield, Aaron S., et al.
Publicado: (2021)

Commentary: Restructuring residency training in ophthalmology during COVID-19 era: Challenges and opportunities
por: Kumar, Atul, et al.
Publicado: (2020)

Commentary on the opportunities of research in Geriatrics and Gerontology
por: Chan, Daniel Kam Yin, et al.
Publicado: (2018)

Antitumour activity of pembrolizumab in advanced mucosal melanoma: a post-hoc analysis of KEYNOTE-001, 002, 006
por: Hamid, Omid, et al.
Publicado: (2018)

Immune checkpoint inhibitors in lymphoma: challenges and opportunities
por: Hatic, Haris, et al.
Publicado: (2021)

Hyperprogression and Immune Checkpoint Inhibitors: Hype or Progress?
por: Adashek, Jacob J., et al.
Publicado: (2019)

A Review About Pembrolizumab in First-Line Treatment of Advanced NSCLC: Focus on KEYNOTE Studies
por: Qu, Jialin, et al.
Publicado: (2020)

Pembrolizumab Plus Chemotherapy for Chinese Patients With Metastatic Squamous NSCLC in KEYNOTE-407
por: Cheng, Ying, et al.
Publicado: (2021)

ESMO20 YO for YO: highlights on metastatic NSCLC-Keynote 024 update
por: Mariamidze, E., et al.
Publicado: (2021)

Translating KEYNOTE-048 into practice recommendations for head and neck cancer
por: Szturz, Petr, et al.
Publicado: (2020)

Keynotes
Publicado: (2023)

Using Model‐Based “Learn and Confirm” to Reveal the Pharmacokinetics‐Pharmacodynamics Relationship of Pembrolizumab in the KEYNOTE‐001 Trial
por: Elassaiss‐Schaap, J, et al.
Publicado: (2016)

Pembrolizumab KEYNOTE-001: an adaptive study leading to accelerated approval for two indications and a companion diagnostic
por: Kang, S. P., et al.
Publicado: (2017)

How I treat ALK-positive non-small cell lung cancer
por: McCusker, Michael G, et al.
Publicado: (2019)

Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Opportunities and Challenges
por: Liu, Xiufeng, et al.
Publicado: (2019)

KEYNOTE-407: new hope for the treatment of lung squamous cell carcinoma
por: Zhao, Xinmin, et al.
Publicado: (2020)

Keynote 42: Pembrolizumab, PD-L1, and where to draw the line
por: Isaacs, James, et al.
Publicado: (2020)

Considerations for adjuvant immunotherapy in stage II melanoma: KEYNOTE-716 and beyond
por: Chen, Lanyi Nora, et al.
Publicado: (2023)

CERN Keynote: CERN and Data Analytics Challenges
por: GRANCHER, Eric
Publicado: (2014)

Commentary: Squamous cell carcinoma of the esophagus: Another target for checkpoint inhibition
por: Whyte, Richard I.
Publicado: (2022)

Opportunities and Challenges for the Emerging Field of Positive Emotion Regulation: A Commentary on the Special Edition on Positive Emotions and Cognitions in Clinical Psychology
por: Dunn, Barnaby D.
Publicado: (2017)

Challenges in assessing the clinical utility and economic value of immune checkpoint inhibitor therapies of Cancer
por: Yu, Peter Paul, et al.
Publicado: (2019)

Commentary: The challenges of treating retinoblastoma in India
por: Shah, Parag K
Publicado: (2019)

Commentary: The challenges of managing suprachoroidal hemorrhage
por: Bhende, Pramod S, et al.
Publicado: (2021)

Keynote Address
por: Zinsou, Lionel
Publicado: (2019)

Keynote Address
por: Cherkaoui El Moursli, Rajaa
Publicado: (2019)

Keynote Address
por: Schönenberger, Klaus
Publicado: (2019)

Welcome & Keynote
por: Martin, Robert "Uncle Bob"
Publicado: (2019)

Keynote Address
por: Bordry, Frederick
Publicado: (2019)

Keynote presentations
por: Desai, Nitin, et al.
Publicado: (2004)

Keynote Lectures
Publicado: (2004)

Cannot write session to /tmp/vufind_sessions/sess_v3mecinj5b3bgkb69c9p1d2p6u